Skip Nav Destination
Issues
1 May 2014
-
Cover Image
Cover Image
Lung squamous cell carcinoma (SCC) is thought to arise from premalignant lesions in the airway epithelium; therefore, studying these lesions is critical for understanding lung carcinogenesis. RNA sequencing was performed on laser-microdissected representative cell populations along the SCC pathological continuum of patient-matched normal basal cells, premalignant lesions, and tumor cells. Transcriptomic changes and genomic pathways altered with initiation and progression of SCC within individual patients were identified. Immunofluorescent staining confirmed gene expression changes in premalignant lesions and tumor cells, including increased expression of SLC2A1, CEACAM5, and PTBP3 at the protein level and increased activation of MYC via nuclear translocation. The cover micrograph shows merged immunofluorescently stained SCCs (PTBP3, green; KRT5, red; nuclei, blue) showing increased expression of PTBP3 in KRT5-expressing premalignant lesions and SCCs compared to basal cells in normal airway epithelium (not shown). The present study is the first gene expression profiling study of airway premalignant lesions with patient-matched normal airway epithelium and SCC samples, and provides much needed information about the biology of premalignant lesions and the molecular changes that occur during stepwise carcinogenesis of SCC. Importantly, it highlights a novel approach for identifying some of the earliest molecular changes associated with initiation and progression of lung carcinogenesis within individual patients. See the article by Ooi and colleagues (beginning on page 487) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Review
Research Articles
Molecular Profiling of Premalignant Lesions in Lung Squamous Cell Carcinomas Identifies Mechanisms Involved in Stepwise Carcinogenesis
Aik T. Ooi; Adam C. Gower; Kelvin X. Zhang; Jessica L. Vick; Longsheng Hong; Brian Nagao; W. Dean Wallace; David A. Elashoff; Tonya C. Walser; Steven M. Dubinett; Matteo Pellegrini; Marc E. Lenburg; Avrum Spira; Brigitte N. Gomperts
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
Kenneth G. Linden; Sancy A. Leachman; Jonathan S. Zager; James G. Jakowatz; Jaye L. Viner; Christine E. McLaren; Ronald J. Barr; Philip M. Carpenter; Wen-Pin Chen; Craig A. Elmets; Joseph A. Tangrea; Sung-Jig Lim; Alistair J. Cochran; Frank L. Meyskens, Jr
SERMs Attenuate Estrogen-Induced Malignant Transformation of Human Mammary Epithelial Cells by Upregulating Detoxification of Oxidative Metabolites
L.P. Madhubhani P. Hemachandra; Hitisha Patel; R. Esala P. Chandrasena; Jaewoo Choi; Sujeewa C. Piyankarage; Shuai Wang; Yijin Wang; Emily N. Thayer; Robert A. Scism; Bradley T. Michalsen; Rui Xiong; Marton I. Siklos; Judy L. Bolton; Gregory R.J. Thatcher
Author Choice
Methylation of Twelve CpGs in Human Papillomavirus Type 16 (HPV16) as an Informative Biomarker for the Triage of Women Positive for HPV16 Infection
Janet L. Brandsma; Malini Harigopal; Nancy B. Kiviat; Ying Sun; Yanhong Deng; Daniel Zelterman; Paul M. Lizardi; Veronika S. Shabanova; Angelique Levi; Tian Yaping; Xinyuan Hu; Qinghua Feng
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.